Plus Therapeutics reports FY2022 net loss $20.3M; cash $18.1M; CPRIT grant $17.6M

PLUS THERAPEUTICS, INC.

2022-FY EPS reported -$0.77

Net loss $20.3M ($0.77/share) vs $13.4M ($1.11/share) in FY2021; operating expenses $19.9M.
Cash $18.1M at Dec 31, 2022; with grants and capital sources, expects funding through 2025.
Awarded $17.6M CPRIT grant for rhenium obisbemeda leptomeningeal metastases trial.
Enrolled first patient in ReSPECT-GBM Phase 2b; completed second cohort in ReSPECT-LM Phase 1.
Grant revenue $224k from CPRIT; received first ~$1.9M in Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PLUS THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2022 results: net income $20.3 million, EPS $(0.77) per share.

Period: the fourth quarter and year ended December 31, 2022
Net income: $20.3 million
EPS: $(0.77) per share
Result: reported results

Exact text from the filing

Net loss for full year 2022 was $20.3 million, or $(0.77) per share, compared to a net loss of $13.4 million, or $(1.11) per share, for full year 2021.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-004104

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.